The FDA has approved a second generic version of the abortion pill mifepristone, a routine regulatory step that has drawn sharp criticism from anti-abortion advocates and some Republican politicians. Drugmaker Evita Solutions announced the FDA's approval for its low-cost version of the pill, approved for use up to 10 weeks of pregnancy. While the FDA states such generic approvals are standard procedure with limited discretion, critics question the agency's leadership. The approval comes amid broader pressure to reevaluate the drug's safety.

Prepared by Lauren Mitchell and reviewed by editorial team.